Influence of BCG-Potentiated Immunotherapy in Tumor-Bearing Mice 2
- 1 August 1977
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 59 (2) , 359-365
- https://doi.org/10.1093/jnci/59.2.359
Abstract
In (C57BL/6 × DBA/2)F1 mice, therapy of a murine mastocytoma P815 (MA) was attempted based on a model of BCG-potentiated antitumor immunity in which a tumor Immunogen (Irradiated MA cells) injected sc Into a site previously inoculated with BCG elicited both delayed-type hypersensitivity and specific systemic Immunity. Immunization, begun as early as 1 or 7 days after tumor implantation, failed to produce detectable tumor resistance in situ. However, lymphoid cells from these immunized mice could transfer local antitumor immunity. This local antitumor immunity was almost as effective as that transferred from non-tumor-bearing immunized mice and was considerably more potent than that transferred from “normal” tumor-bearing mice which showed concomitant Immunity. BCG-potentlated lymphoid cells continued to suppress admixed MA cells after local transfer to recipients bearing previously established MA.Keywords
This publication has 0 references indexed in Scilit: